The concomitant administration of DOACs with anti-cancer and adjunctive pharmacotherapies that are inhibitors or inducers of Pg-P and CYP3A4 poses a theoretical risk of VTE or bleeding by pushing circulating DOAC levels outside the therapeutic range. The gene discussed is PGP; the disease is cancer.